GSK to launch once every 3 month injectable drug for osteoporosis.

GSK Korea announced to launch Bonviva (ibandronate), an anti-osteoporosis therapy for menopause women, once every 3 month injectable administration via intra-vein.

Bonviva is a class of the biphosphonate drugs with an excellent efficacy and tolerance approved locally as an oral drug, administering once a month.

An oral bisphosphonate preparation shows an excellent protective effect agains...